You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: LABAs are better than leukotriene receptor antagonists when added to inhaled corticosteroids in recurrent asthma

https://doi.org/10.1136/ebm.12.3.82

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;(4):CD003137.
    OpenUrlPubMed

    
 
 Q In patients with recurrent asthma, what is the effectiveness of adding long acting β2 agonists (LABAs) or leukotriene receptor antagonists (LTRAs) to inhaled corticosteroids (ICSs)?

    Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★★☆ Allergy & immunology ★★★★★★☆ Paediatrics ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    Medline, CINAHL, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, Cochrane Airways Group Specialised Register (to March 2006), hand searches of respiratory journals and meeting abstracts, and bibliographies of relevant published and unpublished studies and reviews.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) that evaluated the effectiveness of adding LABAs (salmeterol or formoterol) or LTRAs (montelukast, pranlukast, zafirlukast, or zileuton) to ICSs for recurrent asthma. Rescue and asthma medications were permitted at a constant dose. 15 RCTs (age range …

    View Full Text

    Footnotes

    • For correspondence: Professor F Ducharme, The Montreal Children’s Hospital, Montreal, Quebec, Canada. francine.ducharme{at}muhc.mcgill.ca

    • Sources of funding: Nederlands Asthma Fonds Netherlands and NHS Research and Development.